Recently added

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

STRADELLA, AGOSTINA; Johnson, Melissa L.; GOEL, SANJAY; Park, Haeseong; Saavedra, Omar; Lakhani, Nehal; Arkenau, Hendrik-Tobias (Wiley, 2024-07)

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

Casartelli, Chiara; Tommasi, Chiara; Lazzarin, Alessandro; Corianò, Matilde; Tornali, C.; Serra, Olga; Gutiérrez-Enríquez, Sara; Llop-Guevara, Alba; Serra, Violeta (Elsevier, 2024-07-05)

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

Brose, Marcia; Bastholt, Lars; Führer-Sakel, Dagmar; Leboulleux, Sophie; Capdevila Castillon, Jaume; ELISEI, ROSSELLA (Bioscientifica, 2024-07-02)

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

klein, christophe; Blanc-Durand, Felix; LE FORMAL, Audrey; Yaniz-Galende, Elisa; ZENG, Qinghe; Grau Bejar, Juan Francisco (American Association for Cancer Research, 2024-07-01)

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

SANCHO, JUAN-MANUEL; Kumar, Abhijeet; Cordoba, Raul; Tani, Monica; Langmuir, Peter; Abrisqueta, Pau (Taylor & Francis, 2024-07)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors ﻿

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents ﻿

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy ﻿

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy ﻿

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) ﻿

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)